Sensorion announces financing of 15 million euros, and extends its cash horizon until the end of 2025
•
Support from existing investors, including Redmile Group, Invus, Sofinnova Partners and a major investment management company
•
The financing will allow the Company to extend its cash horizon until the end of 2025.
Montpellier, April 8, 2024, at 7:30 a.m. CET – Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company dedicated to the development of innovative therapies to restore, treat and prevent hearing loss, today announces the completion of a placement of a gross amount of 15 million euros reserved for specific categories of investors (the “Private Placement”), through the issue of 24,574,694 ordinary shares by the Company (the “New Shares “), at a price per New Share of €0.63 (the “Subscription Price”) for the benefit of existing shareholders including Redmile Group, Invus, Sofinnova Partners and a major investment management company. Payment and delivery